PMID- 21540087
OWN - NLM
STAT- MEDLINE
DCOM- 20120123
LR  - 20131121
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 413
IP  - 1-2
DP  - 2011 Jul 15
TI  - Inhalation performance of pollen-shape carrier in dry powder formulation: effect 
      of size and surface morphology.
PG  - 93-102
LID - 10.1016/j.ijpharm.2011.04.033 [doi]
AB  - In a previous study, pollen-shape drug carriers are compared with traditional 
      carriers at different drug mixing ratios and flow rates. It is found that 
      pollen-shape drug carriers can deliver large amount of drug particles and reduce 
      drug losses especially at low flow rates and high drug mixing ratios. In this 
      study, the effect of size and surface morphology of pollen-shape carriers on drug 
      delivery performance is assessed. Pollen-shape carrier particles having various 
      sizes and surface asperities are synthesized. Budesonide (Bd) is used as the 
      model drug. The drug delivery performances of the pollen-shape carrier particles 
      are investigated using an Andersen Cascade Impactor (ACI) equipped with a 
      Rotahaler at gas flow rates of 30 and 60 L/min. Three drug mixing ratios are 
      considered. While an increase in the carrier particle size has a mild improvement 
      on the ED, it significantly improves the FPF. A sparse surface asperity has 
      negligible effect on the ED at low flow rates but it improves the FPF compared to 
      a dense surface asperity under all experimental conditions.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Hassan, Meer Saiful
AU  - Hassan MS
AD  - School of Chemical and Biomedical Engineering, Nanyang Technological University, 
      Singapore.
FAU - Lau, Raymond
AU  - Lau R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110421
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Aerosols)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Excipients)
RN  - 0 (Powders)
RN  - 51333-22-3 (Budesonide)
RN  - 91D9GV0Z28 (Durapatite)
SB  - IM
MH  - Administration, Inhalation
MH  - Aerosols
MH  - Bronchodilator Agents/administration & dosage/analysis/*chemistry
MH  - Budesonide/administration & dosage/analysis/*chemistry
MH  - Drug Carriers/*chemistry
MH  - Drug Compounding
MH  - *Drug Delivery Systems
MH  - Durapatite/analysis/chemical synthesis
MH  - Excipients/chemistry
MH  - Molecular Structure
MH  - Nebulizers and Vaporizers
MH  - Particle Size
MH  - Pollen/chemistry
MH  - Powders/chemistry
MH  - Surface Properties
EDAT- 2011/05/05 06:00
MHDA- 2012/01/24 06:00
CRDT- 2011/05/05 06:00
PHST- 2010/12/15 00:00 [received]
PHST- 2011/03/08 00:00 [revised]
PHST- 2011/04/15 00:00 [accepted]
PHST- 2011/05/05 06:00 [entrez]
PHST- 2011/05/05 06:00 [pubmed]
PHST- 2012/01/24 06:00 [medline]
AID - S0378-5173(11)00360-7 [pii]
AID - 10.1016/j.ijpharm.2011.04.033 [doi]
PST - ppublish
SO  - Int J Pharm. 2011 Jul 15;413(1-2):93-102. doi: 10.1016/j.ijpharm.2011.04.033. 
      Epub 2011 Apr 21.